Erratum

This article refers to:

Selective estrogen receptor modulators in clinical practice: a safety overview

Correction to: Selective estrogen receptor modulators in clinical practice: a safety overview.

Ellis AJ, Hendrick VM, Williams R, Komm BS. Selective estrogen receptor modulators in clinical practice: a safety overview. Expert Opin. Drug Saf. 2015;14(6):921-34.

Following publication of this article, it was identified that Table 3 was missed in the PDF version of the article. Table 3 is given below:

Table 3. Major cardiovascular, cerebrovascular, and thromboembolic events associated with selective estrogen receptor modulators.

	Tamoxifen	Raloxifene	Toremifene	Bazedoxifene	Lasofoxifene	Ospemifene	Fulvestrant
	IBIS-I (n = 7152) 20 mg/day [28] NSABP (n = 13,388) 20 mg/day [27]	MORE (n = 7705) 60 mg/day 120 mg/day [6] MORE + CORE (n = 4011) 60 mg/day [36] RUTH (n = 10,101) 60 mg/day [29]	Nordic Trial (n = 415) 60 mg/day [37] Eastern Europe/Russia (n = 463) 60 mg/day, 240 mg/day [38] International (n = 648) 60 mg/day, 200 mg/day [39] IBCSG (n = 1035) 60 mg/day [40]	Osteoporosis treatment, 3-year (n = 7492) 20 mg/day, 40 mg/day [30], 5-year (n = 5643) 20 mg/day, 40/20 mg/day [31], 7-year (n = 1732) 20 mg/day, 40 mg/day [41,65] Osteoporosis prevention (n = 1583) 10, 20, 40 mg/day [32]	PEARL (n = 8559) 0.25 and 0.5 mg/day [56]	12-week VVA l (n = 826) 30 mg/day, 60 mg/day [42] 1-year extension (n = 180)* 30 mg/day, 60 mg/day [34] 12-week VVA (n = 605) 60 mg/day [35]	Trials 1 & 2 versus anastrozole (n = 851) 250 mg [58] Trial 3 versus tamoxifen (n = 587) 250 mg [59] Trial 4: CONFIRM (n = 736) 250 mg, 500 mg [60]
Event
All VTE	OR: 2.5^‡ [28]	0.9 – 1.0% [6] 1.7% [36] 0.39% [29]	5.1% [37] 1.9, 0.6% [38] 3.0, 2.0% [39]	HR: 1.6, 1.7 [30] HR: 1.5, 1.7 [31] 0.9% (all doses) [65]	HR: 2.7^‡, 2.1^¶ [56]	0, 0% [42] 0, 0% [34] 0% [35]	3.5% [58] 5.8% [59] 1.6, 0.8% [60]
DVT	OR: 1.60 [27]	0.7 – 0.8% [6] 1.1% [36] 0.24% [29]	n = 2 [40]	HR: 8.0, 9.4 [30] HR: 3.0, 3.8 [31] 0.0, 0.6% [32] 0.5% (all doses) [65]	HR: 2.8^§, 2.2^¶	n = 0	NR
PE	OR: 3.01 [27]	0.3 – 0.4% [6] 0.62% [36] 0.14% [29]	n = 1 [40] 2.3, 0.9% [39]	HR: 0.8, 0.8 [30] HR: 1.0, 0.8 [31] 0.0, 0.3% [32] 0.2% (all doses) [65]	HR: 6.0^§, 4.5^¶	n = 0	NR
Retinal vein thrombosis	NR	NR	NR	HR: 0.7, 0.4 [30] HR: 0.7, 0.7 [31] 0.0% [32] 0.1% (all doses) [65]	NR	n = 0	NR
All Stroke/TIA	OR: 1.59 [27] OR: ∼ 1 [28]	NR [6] 2.9% [36] 0.95% [29]	NR [37] 0, 1.4% [39] n = 3 [40]	Stroke HR: 0.9, 1.0 [30] HR: 0.8, 0.9 [31] 0 [32] 1.1% (all doses, years 0 – 7) [65] TIA HR: 1.3, 1.8 [30] HR: 1.5, 3.1 [31] 0.5% (all doses) [65]	Stroke HR: 0.61^¶, 0.64^¶ TIA HR: 1.4, 1.0 [56]	All stroke/TIA: 0% [42] 0, 0% [34] 0% [35]	NR
All ischemic cardiac events	OR: 1.15 [27] OR: ∼ 1 [28]	MI: 2.6% [36]	MI: n = 1 [40] 0.9, 0.5% [39] All cardiac events (%): 3.3 [37] 1.3, 0.0% [38] 2.0, 1.0% [39]	MI: 0.6% (all doses) [65]	HR: 0.8, 0.7^¶ [56]	0% [42] 0, 0% [34] 0% [35]	0% [58] 0% [59] 1.9, 1.4% [60]

All VTE includes pulmonary embolism, DVT, retinal vein thrombosis, other thrombosis; all stroke/TIA includes fatal and nonfatal stroke and transient ischemic attack; all ischemic cardiac events includes myocardial infarction (fatal and nonfatal), coronary revascularization, severe angina, and other cardiovascular events.

*This analysis included extension trial data only from women with a uterus.

^‡p < 0.001 versus placebo.

^§p < 0.01 versus placebo.

^¶p < 0.05 versus placebo.

CONFIRM: Comparison of Faslodex in Recurrent or Metastatic Breast Cancer; CORE: Continuing Outcomes Relevant to Evista; DVT: Deep vein thrombosis; IBCSG: International Breast Cancer Study Group; IBIS: International Breast Cancer Intervention Study; HR: Hazard ratio versus placebo; MI: Myocardial infarction; MORE: Multiple Outcomes of Raloxifene Evaluation; NA: Not applicable; NSABP: National Surgical Adjuvant Breast and Bowel Project; NR, not reported; OR: Odds ratio versus placebo; PEARL: Postmenopausal Evaluation and Risk-Reduction with Lasofoxifene; RR: Relative risk versus placebo; RUTH: Raloxifene Use for the Heart study; TIA: Transient ischemic attack; VTE: Venous thromboembolism; VVA: Vulvar–vaginal atrophy.